{"api_version":"v1","date":"2026-05-20","conference":null,"generated_at":1779299437563,"digest":{"top_line":"LS-SCLC 54 Gy SIB vs 45 Gy: mOS 60.7 vs 39.5mo, HR 0.55 — dose escalation via SIB clears the toxicity bar.","tldr":"Thoracic carried today's headline: a Chinese phase 3 trial (NCT03214003) shows 54 Gy SIB nearly halves the OS hazard vs standard 45 Gy BID in LS-SCLC, with no toxicity increase. Breast added a retrospective PBS proton vs IMRT capsular contracture comparison, though no effect size was recoverable from the source.","sites":[{"disease_site":"breast","intro":null,"studies":[{"name":"PBS Proton vs IMRT Capsular Contracture Post-Mastectomy","tldr":"PBS proton vs IMRT in post-mastectomy reconstruction: capsular contracture risk comparison; no effect size reported in source.","details":["🔍 Retrospective comparative study, post-mastectomy reconstruction setting, PBS proton vs IMRT","📊 Primary question: does PBS proton PMRT carry higher capsular contracture risk vs IMRT? No effect size reported in source","⚠️ Full text not available; no outcomes data extractable from citation alone","⚠️ Likely single-institution retrospective; PBS cohort selection bias plausible (proton pts may carry lower baseline reconstruction risk)","🔗 Capsular contracture is a recognized late toxicity endpoint in post-mastectomy RT; prior photon data suggest dose heterogeneity as a driver","❓ Whether PBS proton's sharper dose falloff translates to lower implant toxicity vs IMRT remains an open clinical question"],"key_figure_url":null,"key_figure_caption":null,"nct":null,"tweet_ids":[1000000006],"slug":"pbs-proton-capsular-contracture-pmrt","verdict":{"soc_implication":"unclear","rationale":"Citation only; no outcomes data in source. Cannot assess design validity, effect direction, or magnitude.","audience":"Post-mastectomy pts undergoing implant reconstruction, PMRT candidates"},"open_questions":["Does PBS proton reduce capsular contracture vs IMRT in implant reconstruction?","Is selection bias driving any observed difference in proton cohorts?"],"source_ids":[{"type":"paper","id":6}]}],"open_questions":null},{"disease_site":"thoracic","intro":"Dose escalation in LS-SCLC gets its strongest OS signal yet, via SIB rather than overall dose or fractionation change.","studies":[{"name":"LS-SCLC 54 Gy SIB vs 45 Gy (NCT03214003)","tldr":"54 Gy SIB vs 45 Gy in LS-SCLC: mOS 60.7 vs 39.5mo, HR 0.55 (0.37-0.72), p=0.003, no toxicity increase.","details":["📊 1° EP (OS, ITT): mOS 60.7mo (95% CI 49.2-62.0) vs 39.5mo (27.5-51.4), HR 0.55 (0.37-0.72), p=0.003","🔍 Phase 3 open-label, N=224 (54 Gy n=108, 45 Gy n=116), 16 hospitals in China, median f/u 46mo","🔍 Both arms: VMAT BID (10 fx/wk × 3wks), PTV 45 Gy/30 fx; SIB arm added GTV boost to 54 Gy/30 fx","💊 Concurrent cisplatin or carboplatin + etoposide; PCI 25 Gy/10 fx in responders (both arms)",{"text":"📊 G3-4 RT toxicities (54 Gy vs 45 Gy)","subdetails":["Oesophagitis: 13% vs 12%, p=0.84","Pneumonitis: 5% vs 6%, p=0.663","1 treatment-related death (MI) in 54 Gy arm"]},"⚠️ Trial stopped early by DSMB (Apr 2021) on benefit grounds — early termination inflates effect size estimates","⚠️ China-only, ECOG 0-1, age 18-70; generalizability to older/PS2 pts and Western populations uncertain","🔗 vs Turrisi 45 Gy BID (NEJM 1999): that landmark established 45 Gy BID as SOC; this trial uses same schedule with SIB boost to escalate GTV dose while holding PTV constant","🔗 vs CONVERT (Lancet Oncol 2017): 45 Gy BID non-inferior to 66 Gy QD — this trial takes a different approach (dose-escalate via SIB, not overall dose/fractionation change)","❓ Whether benefit holds with modern immunotherapy-containing regimens (atezolizumab/durvalumab consolidation now emerging in LS-SCLC)"],"key_figure_url":null,"key_figure_caption":null,"nct":"NCT03214003","tweet_ids":[1000000007],"slug":"ls-sclc-54gy-vs-45gy-sib","verdict":{"soc_implication":"challenges-soc","rationale":"Randomised phase 3, OS primary endpoint hit, adequate f/u. Directly contests 45 Gy BID as SOC for LS-SCLC, though early stopping and China-only enrollment are caveats.","audience":"LS-SCLC, untreated or 1 prior chemo cycle, ECOG 0-1, age 18-70"},"open_questions":["Replication in Western/multinational cohort","Benefit maintained with IO consolidation added?","Optimal patient selection (stage IIA vs IIIB, tumour volume)?"],"source_ids":[{"type":"paper","id":7}]}],"open_questions":null}],"meta":{"clusters_total":2,"studies_analyzed":2,"dropped":[],"ocr_available":true}},"bookmarks":[],"papers":[{"id":7,"pmid":null,"doi":"10.1016/s2213-2600(24)00189-9","pmc_id":null,"title":"High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial","authors":["Jiayi Yu","Leilei Jiang","Lina Zhao","Xue Yang","Xiaomin Wang","Dan Yang","Minglei Zhuo","Hanxiao Chen","Wei Huang","Zhengfei Zhu","Min Zhang","Yipeng Song","Quanfu Li","Zhanshu Ma","Qifeng Wang","Yanli Qu","Rong Yu","Huiming Yu","Jun Zhao","Anhui Shi"],"journal":"Lancet Respiratory Medicine","pub_date":"2024-08-12","abstract":"Background For the past 20 years, twice-daily thoracic radiotherapy with concurrent chemotherapy has been the treatment of choice for limited-stage small-cell lung cancer (LS-SCLC), which has a poor prognosis. We aimed to assess the efficacy and safety of high-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) versus standard-dose radiotherapy (45 Gy in 30 fractions) as a first-line treatment for LS-SCLC.\nMethods This open-label, randomised, phase 3 trial was performed at 16 public hospitals in China. The key inclusion criteria were patients aged 18–70 years, with histologically or cytologically confirmed LS-SCLC, who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, and who were previously untreated or had received one course of cisplatin or carboplatin and etoposide. Eligible patients were randomly assigned (1:1) to receive volumetric-modulated arc radiotherapy (VMAT) of 45 Gy in 30 fractions to the gross tumour volume or VMAT with a simultaneous integrated boost of 54 Gy in 30 fractions to the gross tumour volume starting 0–42 days after the first chemotherapy course. Both groups received 10 fractions of twice-daily thoracic radiotherapy per week. The planning target volume was 45 Gy in 30 fractions in both groups. Patients with responsive disease received prophylactic cranial radiotherapy (25 Gy in 10 fractions). Randomisation was performed using a centralised interactive web response system, stratified by ECOG performance status, disease stage, previous chemotherapy course, and chemotherapy choice. The primary outcome was overall survival in the intention-to-treat population. Safety was analysed in the as-treated population. This study was registered at ClinicalTrials.gov, NCT03214003.\nFindings From June 30, 2017, to April 6, 2021, 224 patients (102 [46%] females and 122 [54%] males; median age 64 years [IQR 58–68]) were enrolled and randomly assigned to the 54 Gy group (n=108) or 45 Gy (n=116) group. The median follow-up was 46 months (IQR 33–56). The median overall survival was significantly longer in the 54 Gy group (60·7 months [95% CI 49·2–62·0]) than in the 45 Gy group (39·5 months [27·5–51·4]; hazard ratio 0·55 [95% CI 0·37–0·72]; p=0·003). Treatment was tolerable, and the chemotherapy-related and radiotherapy-related toxicities were similar between the groups. The grade 3–4 radiotherapy toxicities were oesophagitis (14 [13%] of 108 patients in the 54 Gy group vs 14 [12%] of 116 patients in the 45 Gy group; p=0·84) and pneumonitis (five [5%] of 108 patients vs seven [6%] of 116 patients; p=0·663). Only one treatment-related death occurred in the 54 Gy group (myocardial infarction). The study was prematurely terminated by an independent data safety monitoring board on April 30, 2021, based on evidence of sufficient clinical benefit.\nInterpretation Compared with standard-dose thoracic radiotherapy (45 Gy), high-dose radiotherapy (54 Gy) improved overall survival without increasing toxicity in a cohort of patients aged 18–70 years with LS-SCLC. Our results support the use of twice-daily accelerated thoracic radiotherapy (54 Gy) with concurrent chemotherapy as an alternative first-line LS-SCLC treatment option.","note":null},{"id":6,"pmid":null,"doi":"10.1016/j.ijrobp.2025.07.1298","pmc_id":null,"title":"Does Pencil Beam Scanning Proton Therapy Impart a Higher Risk of Capsular Contracture when Compared with Intensity Modulated Photon Radiotherapy in the Post-Mastectomy Reconstruction Setting?","authors":["Zerey, M.M.","Gal, O.","Feenstra, N.","Hodgson, L.","Fagundes, M.A.","Rodrigues, M.A.M.","Botero, A.C.","Gutierrez, A.","Wroe, A.","Fellows, Z.","Medina, M.A.","Panoff, J.E."],"journal":"International Journal of Radiation Oncology*Biology*Physics","pub_date":"2025-09","abstract":null,"note":"https://doi.org/10.1016/j.ijrobp.2025.07.1298"}]}